What is antibody sequencing?

Antibody sequencing is the process of determining the precise order of amino acids in an antibody's variable regions. This sequencing reveals the unique structure of the antigen-binding sites, providing critical insights into the antibody's specificity and interaction with antigens.

How does antibody sequencing contribute to identifying T-cell epitopes?

By determining the sequences of antibodies, researchers can identify the binding regions that interact with antigens, which may include T-cell epitopes. Sequencing helps predict how these epitopes are presented to T-cells, crucial for understanding immune responses and designing less immunogenic therapeutic antibodies.

What role does antibody sequencing play in antibody drug de-immunization?

Antibody sequencing allows for the identification of immunogenic regions within an antibody. By pinpointing these regions, scientists can modify the sequence to reduce immunogenicity without compromising the antibody's therapeutic function, thus enhancing the safety and efficacy of antibody drugs.

What technologies are used for antibody sequencing?

Technologies used for antibody sequencing include next-generation sequencing (NGS), mass spectrometry-based sequencing, and traditional Sanger sequencing. NGS offers high-throughput capabilities, enabling comprehensive profiling and analysis of multiple antibodies simultaneously.

Can antibody sequencing alone identify T-cell epitopes?

While antibody sequencing is critical, it does not alone identify T-cell epitopes. It needs to be combined with immunoinformatics tools that predict MHC binding and T-cell receptor interaction, and experimental validation to confirm the biological relevance of the predicted T-cell epitopes.

What improvements have recent advances in antibody sequencing brought to de-immunization strategies?

Recent advances in antibody sequencing have improved the accuracy and speed of identifying immunogenic regions. High-throughput sequencing and enhanced computational models now allow for rapid screening and optimization of therapeutic antibodies, facilitating more effective de-immunization strategies.

What are the limitations of antibody sequencing in the context of de-immunization?

Sequencing alone may not predict all potential immunogenic responses, especially those involving complex conformational epitopes that are not readily apparent from primary sequence data. Additional structural and functional assays are often necessary to fully understand and mitigate immunogenicity.

RDIT^® Antibody Sequencing Service

Background Features FAQ Resources

The root cause of the body's immunogenicity is that its protein sequence is present on the surface of T cells, which can activate T cells, resulting in the body's continuous production of a large number of antibodies, thereby reducing the therapeutic effect of the drug.

De-immunization is a new technique to remove T cell epitopes by combining immunological and molecular biology techniques. After antibody de-immunization, it is usually possible to reduce the localization of T cells and have no effect on the affinity of antibody binding. Based on our unique and comprehensive platform, Creative Biolabs provides antibody sequencing to reduce immunogenicity and improve the therapeutic effect of the drug.

De-immunization by Antibody Sequencing

Successful recognition and removal of immunodominant CD4⁺ T cell epitopes can significantly reduce the incidence and severity of antibody drugs through immune ignorance. Based on the accumulation of knowledge to determine which T cell epitopes may have immunogenicity, we propose a method to reduce or remove immunogenicity.

This method uses antibody sequencing technology as a basis to determine the content and position of T cell epitopes, thereby guiding the de-immunization pathway of antibody drugs.

Technical Protocol

1. Using antibody sequencing to scan the primary structure of the protein, identify the main T cell epitopes, and search for the motifs containing anchored residues.

2. New peptides were synthesized by using the residues which are important for anchoring into major histocompatibility complex (MHC) groove, and the reactivity and immunogenicity of these modified peptide epitopes were tested.

3. Structure and homology analysis guide the targeting and substitution of key amino acids to maintain the required protein activity.

4. Site-directed mutations: target neutral residues that do not bind HLA but are also unlikely to significantly alter the folding and function of the modified protein.

5. Get de-immunization antibody drugs.

Features

Reliable results: our antibody sequencing method is very accurate, user-friendly and very economical.
Integration services: our unique services allow us to guide you through the entire process from target selection to clinical drug candidate drug discovery.
Tailor-made: our experienced team will be assigned to each study, focusing on the progress of the project to ensure that the target is reached or exceeded in the shortest possible time.

Creative Biolabs is a trusted antibody development service provider that has professional technical team to provide excellent antibody sequencing services. With extensive experience in antibody sequencing, we can employ advanced sequencing and immune technology to identify and remove T cell epitopes preferentially. If you are interested in our services, please contact us in time about more details and we are honored to serve you.

Other optional RDIT^® antibody drug de-immunization services:

FAQ

What is antibody sequencing?
Antibody sequencing is the process of determining the precise order of amino acids in an antibody's variable regions. This sequencing reveals the unique structure of the antigen-binding sites, providing critical insights into the antibody's specificity and interaction with antigens.
How does antibody sequencing contribute to identifying T-cell epitopes?
By determining the sequences of antibodies, researchers can identify the binding regions that interact with antigens, which may include T-cell epitopes. Sequencing helps predict how these epitopes are presented to T-cells, crucial for understanding immune responses and designing less immunogenic therapeutic antibodies.
What role does antibody sequencing play in antibody drug de-immunization?
Antibody sequencing allows for the identification of immunogenic regions within an antibody. By pinpointing these regions, scientists can modify the sequence to reduce immunogenicity without compromising the antibody's therapeutic function, thus enhancing the safety and efficacy of antibody drugs.
What technologies are used for antibody sequencing?
Technologies used for antibody sequencing include next-generation sequencing (NGS), mass spectrometry-based sequencing, and traditional Sanger sequencing. NGS offers high-throughput capabilities, enabling comprehensive profiling and analysis of multiple antibodies simultaneously.
Can antibody sequencing alone identify T-cell epitopes?
While antibody sequencing is critical, it does not alone identify T-cell epitopes. It needs to be combined with immunoinformatics tools that predict MHC binding and T-cell receptor interaction, and experimental validation to confirm the biological relevance of the predicted T-cell epitopes.
What improvements have recent advances in antibody sequencing brought to de-immunization strategies?
Recent advances in antibody sequencing have improved the accuracy and speed of identifying immunogenic regions. High-throughput sequencing and enhanced computational models now allow for rapid screening and optimization of therapeutic antibodies, facilitating more effective de-immunization strategies.
What are the limitations of antibody sequencing in the context of de-immunization?
Sequencing alone may not predict all potential immunogenic responses, especially those involving complex conformational epitopes that are not readily apparent from primary sequence data. Additional structural and functional assays are often necessary to fully understand and mitigate immunogenicity.